Q3 earnings swing to loss as revenue rises Travere Therapeutics (TVTX) just delivered third quarter 2026 numbers that pulled investor attention to both sides of the income statement. Revenue reached ...
Travere Therapeutics (NASDAQ:TVTX) reported third-quarter results marked by record FILSPARI sales, continued early adoption in focal segmental glomerulosclerosis (FSGS), and progress across its kidney ...
Travere Therapeutics has delivered a very large 3 year share price gain, which naturally puts the spotlight on whether the ...
Reports Q3 revenue $224.6M, consensus $195.3M. “Strong execution across our business drove another quarter of significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results